Impact on weight of a Doravirine switch in people living with HIV.

ABSTRACT:

Background and objective

Doravirine is among the first-line recommended treatments for people living with HIV (PLHIV) in the 2025 EACS guidelines. As opposed to tenofovir alafenamide or anti-integrase, its use was not associated with weight gain in clinical trials, but limited data are currently available in real life. In this cohort study, we investigated weight variation in PLHIV switching to doravirine.

Methods

A retrospective cohort analysis was conducted in two Parisian hospitals, including all PLHIV switching to doravirine between January 2019 and September 2022. Body Mass Index (BMI) variation was calculated from 48 months before to 36 months after the switch.

Results

Between January 2019 and December 2022, 300 patients were included, with 220 men (73%) and 185

SUBMITTER: Garofoli N 

PROVIDER: S-EPMC12757892 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature